Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2024

Open Access 01-12-2024 | Neuropathic Pain | Research

Implication of system xc− in neuroinflammation during the onset and maintenance of neuropathic pain

Authors: Pauline Beckers, Inês Belo Do Nascimento, Mathilde Charlier, Nathalie Desmet, Ann Massie, Emmanuel Hermans

Published in: Journal of Neuroinflammation | Issue 1/2024

Login to get access

Abstract

Background

Despite the high prevalence of neuropathic pain, treating this neurological disease remains challenging, given the limited efficacy and numerous side effects associated with current therapies. The complexity in patient management is largely attributed to an incomplete understanding of the underlying pathological mechanisms. Central sensitization, that refers to the adaptation of the central nervous system to persistent inflammation and heightened excitatory transmission within pain pathways, stands as a significant contributor to persistent pain. Considering the role of the cystine/glutamate exchanger (also designated as system xc−) in modulating glutamate transmission and in supporting neuroinflammatory responses, we investigated the contribution of this exchanger in the development of neuropathic pain.

Methods

We examined the implication of system xc− by evaluating changes in the expression/activity of this exchanger in the dorsal spinal cord of mice after unilateral partial sciatic nerve ligation. In this surgical model of neuropathic pain, we also examined the consequence of the genetic suppression of system xc− (using mice lacking the system xc− specific subunit xCT) or its pharmacological manipulation (using the pharmacological inhibitor sulfasalazine) on the pain-associated behavioral responses. Finally, we assessed the glial activation and the inflammatory response in the spinal cord by measuring mRNA and protein levels of GFAP and selected M1 and M2 microglial markers.

Results

The sciatic nerve lesion was found to upregulate system xc− at the spinal level. The genetic deletion of xCT attenuated both the amplitude and the duration of the pain sensitization after nerve surgery, as evidenced by reduced responses to mechanical and thermal stimuli, and this was accompanied by reduced glial activation. Consistently, pharmacological inhibition of system xc− had an analgesic effect in lesioned mice.

Conclusion

Together, these observations provide evidence for a role of system xc− in the biochemical processes underlying central sensitization. We propose that the reduced hypersensitivity observed in the transgenic mice lacking xCT or in sulfasalazine-treated mice is mediated by a reduced gliosis in the lumbar spinal cord and/or a shift in microglial M1/M2 polarization towards an anti-inflammatory phenotype in the absence of system xc−. These findings suggest that drugs targeting system xc− could contribute to prevent or reduce neuropathic pain.
Literature
1.
2.
You HJ, Lei J, Sui MY, Huang L, Tan YX, Tjølsen A, Arendt-Nielsen L. Endogenous descending modulation: spatiotemporal effect of dynamic imbalance between descending facilitation and inhibition of nociception. J Physiol. 2010;588(Pt 21):4177–88.PubMedPubMedCentralCrossRef
3.
4.
Saadé NE, Jabbur SJ. Nociceptive behavior in animal models for peripheral neuropathy: spinal and supraspinal mechanisms. Prog Neurobiol. 2008;86(1):22–47.PubMedCrossRef
5.
6.
Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology. 2015;96(Pt A):70–82.PubMedCrossRef
7.
Wu LJ, Steenland HW, Kim SS, Isiegas C, Abel T, Kaang BK, Zhuo M. Enhancement of presynaptic glutamate release and persistent inflammatory pain by increasing neuronal cAMP in the anterior cingulate cortex. Mol Pain. 2008;4:40.PubMedPubMedCentralCrossRef
8.
Carlton SM, Coggeshall RE. Inflammation-induced changes in peripheral glutamate receptor populations. Brain Res. 1999;820(1–2):63–70.PubMedCrossRef
9.
Guo W, Imai S, Zou S, Yang J, Watanabe M, Wang J, et al. Altered glial glutamate transporter expression in descending circuitry and the emergence of pain chronicity. Mol Pain. 2019;15:1744806918825044.PubMedPubMedCentralCrossRef
10.
Cavaliere C, Cirillo G, Rosaria Bianco M, Rossi F, De Novellis V, Maione S, Papa M. Gliosis alters expression and uptake of spinal glial amino acid transporters in a mouse neuropathic pain model. Neuron Glia Biol. 2007;3(2):141–53.PubMedCrossRef
11.
Gegelashvili G, Bjerrum OJ. Glutamate Transport System as a Novel Therapeutic Target in Chronic Pain: Molecular mechanisms and Pharmacology. Adv Neurobiol. 2017;16:225–53.PubMedCrossRef
12.
Gunduz O, Oltulu C, Buldum D, Guven R, Ulugol A. Anti-allodynic and anti-hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. Neurosci Lett. 2011;491(1):23–5.PubMedCrossRef
13.
Hobo S, Eisenach JC, Hayashida K. Up-regulation of spinal glutamate transporters contributes to anti-hypersensitive effects of valproate in rats after peripheral nerve injury. Neurosci Lett. 2011;502(1):52–5.PubMedPubMedCentralCrossRef
14.
Ottestad-Hansen S, Hu QX, Follin-Arbelet VV, Bentea E, Sato H, Massie A, et al. The cystine-glutamate exchanger (xCT, Slc7a11) is expressed in significant concentrations in a subpopulation of astrocytes in the mouse brain. Glia. 2018;66(5):951–70.PubMedCrossRef
15.
Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18(5):522–55.PubMedPubMedCentralCrossRef
16.
Bridges RJ, Natale NR, Patel SA. System xc− cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol. 2012;165(1):20–34.
17.
Massie A, Schallier A, Kim SW, Fernando R, Kobayashi S, Beck H, et al. Dopaminergic neurons of system x(c)−-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. Faseb j. 2011;25(4):1359–69.
18.
De Bundel D, Schallier A, Loyens E, Fernando R, Miyashita H, Van Liefferinge J, et al. Loss of system x(c)- does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J Neurosci. 2011;31(15):5792–803.PubMedPubMedCentralCrossRef
19.
Mesci P, Zaïdi S, Lobsiger CS, Millecamps S, Escartin C, Seilhean D, et al. System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain. 2015;138(Pt 1):53–68.
20.
Pampliega O, Domercq M, Soria FN, Villoslada P, Rodríguez-Antigüedad A, Matute C. Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation. 2011;8:63.
21.
Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med. 2015;7(289):289ra86.PubMedPubMedCentralCrossRef
22.
Merckx E, Albertini G, Paterka M, Jensen C, Albrecht P, Dietrich M, et al. Absence of system x(c)(-) on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis. J Neuroinflammation. 2017;14(1):9.PubMedPubMedCentralCrossRef
23.
Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci. 2005;25(31):7101–10.PubMedPubMedCentralCrossRef
24.
Soria FN, Pérez-Samartín A, Martin A, Gona KB, Llop J, Szczupak B, et al. Extrasynaptic glutamate release through cystine/glutamate antiporter contributes to ischemic damage. J Clin Invest. 2014;124(8):3645–55.PubMedPubMedCentralCrossRef
25.
Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem. 2005;280(45):37423–9.PubMedCrossRef
26.
Malmberg AB, Basbaum AI. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain. 1998;76(1–2):215–22.PubMedCrossRef
27.
28.
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53(1):55–63.PubMedCrossRef
29.
Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32(1):77–88.PubMedCrossRef
30.
Verbruggen L, Sprimont L, Bentea E, Janssen P, Gharib A, Deneyer L, et al. Chronic Sulfasalazine treatment in mice induces System x(c) (-) - independent adverse effects. Front Pharmacol. 2021;12:625699.PubMedPubMedCentralCrossRef
31.
Tsuchihashi K, Okazaki S, Ohmura M, Ishikawa M, Sampetrean O, Onishi N, et al. The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-). Cancer Res. 2016;76(10):2954–63.PubMedPubMedCentralCrossRef
32.
Meikle AD, Martin AH. A rapid method for removal of the spinal cord. Stain Technol. 1981;56(4):235–7.PubMedCrossRef
33.
Xu D, Liu A, Wang X, Zhang M, Zhang Z, Tan Z, Qiu M. Identifying suitable reference genes for developing and injured mouse CNS tissues. Dev Neurobiol. 2018;78(1):39–50.PubMedCrossRef
34.
Košuth J, Farkašovská M, Mochnacký F, Daxnerová Z, Ševc J. Selection of Reliable reference genes for analysis of Gene expression in spinal cord during rat postnatal development and after Injury. Brain Sci. 2019;10(1).
35.
Beckers P, Lara O, Belo do Nascimento I, Desmet N, Massie A, Hermans E. Validation of a system x(c) (-) functional assay in cultured astrocytes and nervous tissue samples. Front Cell Neurosci. 2021;15:815771.PubMedCrossRef
36.
Gallo A, Leerink M, Michot B, Ahmed E, Forget P, Mouraux A, et al. Bilateral tactile hypersensitivity and neuroimmune responses after spared nerve injury in mice lacking vasoactive intestinal peptide. Exp Neurol. 2017;293:62–73.PubMedCrossRef
37.
Zhang B, Wei YZ, Wang GQ, Li DD, Shi JS, Zhang F. Targeting MAPK pathways by Naringenin modulates Microglia M1/M2 polarization in Lipopolysaccharide-Stimulated cultures. Front Cell Neurosci. 2018;12:531.PubMedCrossRef
38.
Liu XJ, Salter MW. Glutamate receptor phosphorylation and trafficking in pain plasticity in spinal cord dorsal horn. Eur J Neurosci. 2010;32(2):278–89.PubMedPubMedCentralCrossRef
39.
Liu SB, Zhang MM, Cheng LF, Shi J, Lu JS, Zhuo M. Long-term upregulation of cortical glutamatergic AMPA receptors in a mouse model of chronic visceral pain. Mol Brain. 2015;8(1):76.PubMedPubMedCentralCrossRef
40.
Qu XX, Cai J, Li MJ, Chi YN, Liao FF, Liu FY, et al. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp Neurol. 2009;215(2):298–307.PubMedCrossRef
41.
42.
Hu Y, Li W, Lu L, Cai J, Xian X, Zhang M, et al. An anti-nociceptive role for ceftriaxone in chronic neuropathic pain in rats. Pain. 2010;148(2):284–301.PubMedCrossRef
43.
Simmons RM, Webster AA, Kalra AB, Iyengar S. Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav. 2002;73(2):419–27.PubMedCrossRef
44.
45.
Burdo J, Dargusch R, Schubert D. Distribution of the cystine/glutamate antiporter system xc- in the brain, kidney, and duodenum. J Histochem Cytochem. 2006;54(5):549–57.PubMedCrossRef
46.
Sato H, Tamba M, Okuno S, Sato K, Keino-Masu K, Masu M, Bannai S. Distribution of cystine/glutamate exchange transporter, system x(c)-, in the mouse brain. J Neurosci. 2002;22(18):8028–33.PubMedPubMedCentralCrossRef
47.
Zhu YF, Linher-Melville K, Wu J, Fazzari J, Miladinovic T, Ungard R, et al. Bone cancer-induced pain is associated with glutamate signalling in peripheral sensory neurons. Mol Pain. 2020;16:1744806920911536.PubMedPubMedCentralCrossRef
48.
Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43(2):205–18.PubMedCrossRef
49.
Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med. 2010;11(12):1859–71.PubMedCrossRef
50.
51.
Patel D, Kharkar PS, Gandhi NS, Kaur E, Dutt S, Nandave M. Novel analogs of sulfasalazine as system x(c)(-) antiporter inhibitors: insights from the molecular modeling studies. Drug Dev Res. 2019;80(6):758–77.PubMedCrossRef
52.
Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia. 2001;15(10):1633–40.PubMedCrossRef
53.
Chung WJ, Sontheimer H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappab. J Neurochem. 2009;110(1):182–93.PubMedPubMedCentralCrossRef
54.
Alcoreza O, Tewari BP, Bouslog A, Savoia A, Sontheimer H, Campbell SL. Sulfasalazine decreases mouse cortical hyperexcitability. Epilepsia. 2019;60(7):1365–77.PubMedPubMedCentralCrossRef
55.
Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, Sontheimer H. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011;17(10):1269–74.PubMedPubMedCentralCrossRef
56.
Miladinovic T, Singh G. Spinal microglia contribute to cancer-induced pain through system x(C) (-)-mediated glutamate release. Pain Rep. 2019;4(3):e738.PubMedPubMedCentralCrossRef
57.
Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, et al. In vitro and in vivo activity of the nuclear factor-kappab inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res. 2004;10(16):5595–603.PubMedCrossRef
58.
59.
Berger JV, Deumens R, Goursaud S, Schäfer S, Lavand’homme P, Joosten EA, Hermans E. Enhanced neuroinflammation and pain hypersensitivity after peripheral nerve injury in rats expressing mutated superoxide dismutase 1. J Neuroinflammation. 2011;8:33.PubMedPubMedCentralCrossRef
60.
61.
Romero-Sandoval A, Chai N, Nutile-McMenemy N, Deleo JA. A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain. Brain Res. 2008;1219:116–26.PubMedPubMedCentralCrossRef
62.
Leinders M, Knaepen L, De Kock M, Sommer C, Hermans E, Deumens R. Up-regulation of spinal microglial Iba-1 expression persists after resolution of neuropathic pain hypersensitivity. Neurosci Lett. 2013;554:146–50.PubMedCrossRef
63.
Honjoh K, Nakajima H, Hirai T, Watanabe S, Matsumine A. Relationship of inflammatory cytokines from M1-Type Microglia/Macrophages at the injured site and lumbar enlargement with Neuropathic Pain after spinal cord Injury in the CCL21 knockout (plt) mouse. Front Cell Neurosci. 2019;13:525.PubMedPubMedCentralCrossRef
64.
Sprimont L, Janssen P, De Swert K, Van Bulck M, Rooman I, Gilloteaux J, et al. Cystine-glutamate antiporter deletion accelerates motor recovery and improves histological outcomes following spinal cord injury in mice. Sci Rep. 2021;11(1):12227.PubMedPubMedCentralCrossRef
65.
Echeverry S, Shi XQ, Yang M, Huang H, Wu Y, Lorenzo LE, et al. Spinal microglia are required for long-term maintenance of neuropathic pain. Pain. 2017;158(9):1792–801.PubMedCrossRef
66.
Guindon J, Blanton H, Brauman S, Donckels K, Narasimhan M, Benamar K. Sex differences in a Rodent Model of HIV-1-Associated Neuropathic Pain. Int J Mol Sci. 2019;20(5).
67.
Ghazisaeidi S, Muley MM, Salter MW. Neuropathic Pain: mechanisms, sex differences, and potential therapies for a global problem. Annu Rev Pharmacol Toxicol. 2023;63:565–83.PubMedCrossRef
68.
Bentea E, Sconce MD, Churchill MJ, Van Liefferinge J, Sato H, Meshul CK, Massie A. MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT. Neurosci Lett. 2015;593:1–6.PubMedCrossRef
69.
Li JX. Pain and depression comorbidity: a preclinical perspective. Behav Brain Res. 2015;276:92–8.PubMedCrossRef
Metadata
Title
Implication of system xc− in neuroinflammation during the onset and maintenance of neuropathic pain
Authors
Pauline Beckers
Inês Belo Do Nascimento
Mathilde Charlier
Nathalie Desmet
Ann Massie
Emmanuel Hermans
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2024
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-024-03112-9

Other articles of this Issue 1/2024

Journal of Neuroinflammation 1/2024 Go to the issue

Research

Lipoxins A4 and B4 inhibit glial cell activation via CXCR3 signaling in acute retinal neuroinflammation

Research

Dimethyl fumarate improves cognitive impairment and neuroinflammation in mice with Alzheimer’s disease

Research

Constitutive knockout of interleukin-6 ameliorates memory deficits and entorhinal astrocytosis in the MRL/lpr mouse model of neuropsychiatric lupus

Research

Thymic gene expression analysis reveals a potential link between HIF-1A and Th17/Treg imbalance in thymoma associated myasthenia gravis

Research

Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes

Research

Fractalkine isoforms differentially regulate microglia-mediated inflammation and enhance visual function in the diabetic retina